Nov 21, 2024 | GLP-1s, MedBen Rx, Wegovy, Weight loss drugs, Zepbound
Bariatric surgeries to treat obesity dropped 25.6% from 2022 to 2023, while prescriptions for GLP-1 drugs more than doubled during that period, according to a new study of privately insured Americans with obesity. However, those who opt for the surgery are...
Sep 3, 2024 | Biosimilar, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Stelara, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
Jun 10, 2024 | Affordable Care Act, Caroline Fraker, Wegovy, Weight loss, Weight loss drugs, Zepbound
While most health plans do not currently cover obesity medications like Wegovy and Zepbound – and MedBen Rx recommends clients continue not to do so – constant media coverage means the calls to do so will only grow. Therefore, employers are increasingly considering...
May 13, 2024 | Diabetes, Kurt Harden, MedBen University, Mounjaro, Ozempic, Wegovy, Weight loss, Zepbound
At recent MedBen University roundtables, MedBen President & CEO Kurt Harden examined how the growing public awareness of two diabetes drugs with a desirable side effect – significant weight loss – means that these $1,000-per-month medications are not always being...
